Paglalarawan

Over the past decade, invasive techniques for diagnosing and monitoring cancers are slowly being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have drastically revolutionized the field of clinical oncology, offering ease in tumor sampling, continuous monitoring by repeated sampling, devising personalized therapeutic regimens, and screening for therapeutic resistance. A study by StrategyHelix indicates that the global liquid biopsy market is expected to increase by US$ 6,579.5 milyon mula sa 2022 sa 2028, garnering a CAGR of 16.1% sa panahon ng pagtataya.

Ang ulat ay nagbibigay ng napapanahong data ng laki ng merkado para sa panahon 2018-2021 at forecast na 2028 covering key market aspects like sales value for liquid biopsy. The global liquid biopsy market is segmented on the basis of therapy, application, biomarker type, teknolohiya, at rehiyon. Based on therapy, the global liquid biopsy market is categorized into oncology, noninvasive prenatal testing (NIPT), iba pa ang iba (e.g. organ transplant). The NIPT segment captured the largest share of the market in 2021. On the basis of application, the global liquid biopsy market has been segmented into diagnosis, early detection/screening, monitoring, therapy guidance. The early detection/screening segment held the largest share of the global liquid biopsy market in 2021 at inaasahang gaganapin ang share nito sa panahon ng pagtataya. By biomarker type, the global liquid biopsy market has been segmented into cell-free nucleic acids, circulating tumor cells, iba pa ang iba. Sa 2021, the cell-free nucleic acids segment made up the largest share of revenue generated by the liquid biopsy market. Based upon technology, the global liquid biopsy market is categorized into next-generation sequencing (NGS), polymerase chain reaction (PCR), iba pa ang iba. Kabilang sa mga ito, the next-generation sequencing (NGS) segment was accounted for the highest revenue generator in 2021. Sa mga tuntunin ng heograpiya, the global liquid biopsy market has been segmented into Asia Pacific, Europa, Hilagang Amerika, Pahinga ng Mundo (RoW).

The global liquid biopsy market is highly competitive. Top players covered in Global Liquid Biopsy Market Study are Adaptive Biotechnologies Corp., Agilent Technologies Inc., Amoy Diagnostics Co. Ltd., Becton Dickinson and Company, Berry Genomics Co. Ltd., BGI Group, Biocartis Group, Biocept Inc., Biodesix Inc., Biolidics Limited, Bio-Rad Laboratories Inc., Bio-Techne Corp., CareDx Inc., Danaher Corp., Eurofins Scientific, EXACT Sciences Corporation, Illumina Inc., Koninklijke Philips N.V., Merck KGaA, Myriad Genetics Inc., NeoGenomics Laboratories Inc., OncoCyte Corporation, Oxford Nanopore Technologies Limited, Pacific Biosciences of California Inc., Qiagen N.V., Roche Holding AG, Takara Bio Inc., Thermo Fisher Scientific Inc., VolitionRx Limited.

Ang ulat ay isang napakahalagang mapagkukunan para sa mga kumpanya at organisasyon na aktibo sa industriyang ito. It provides a cohesive picture of the liquid biopsy market to help drive informed decision making for industry executives, mga gumagawa ng patakaran, akademiko, at mga analyst.

Saklaw ng Ulat

Therapy: oncology, noninvasive prenatal testing (NIPT), iba pa ang iba (e.g. organ transplant)
Paglalapat: diagnosis, early detection/screening, monitoring, therapy guidance
Biomarker type: cell-free nucleic acids, circulating tumor cells, iba pa ang iba
Teknolohiya: next-generation sequencing (NGS), polymerase chain reaction (PCR), iba pa ang iba
Rehiyon: Asya Pasipiko, Europa, Hilagang Amerika, Pahinga ng Mundo (RoW)
Taon na itinuturing: Ang ulat na ito ay sumasaklaw sa panahon 2018 sa 2028

Mga Pangunahing Benepisyo para sa mga Stakeholder

– Get a comprehensive picture of the global liquid biopsy market
– Pinpoint ang mga sektor ng paglago at mga trend para sa pamumuhunan

Talaan ng mga Nilalaman

Bahagi 1. Panimula
– Saklaw ng pag aaral
– Panahon ng pag aaral
– Saklaw ng heograpiya
– Paraan ng pananaliksik
Bahagi 2. Liquid biopsy market overview
Bahagi 3. Market breakdown by therapy
– Oncology
– Noninvasive prenatal testing (NIPT)
– Ang iba naman (e.g. organ transplant)
Bahagi 4. Market breakdown by application
– Diagnosis
– Early detection/screening
– Monitoring
– Therapy guidance
Bahagi 5. Market breakdown by biomarker type
– Cell-free nucleic acids
– Circulating tumor cells
– Ang iba naman
Bahagi 6. Market breakdown by technology
– Next-generation sequencing (NGS)
– Polymerase chain reaction (PCR)
– Ang iba naman
Bahagi 7. Market breakdown by region
– Asya Pasipiko
– Europa
– Hilagang Amerika
– Pahinga ng Mundo (RoW)
Bahagi 8. Mga pangunahing kumpanya
– Adaptive Biotechnologies Corp.
– Agilent Technologies Inc.
– Amoy Diagnostics Co., Ltd.
– Becton, Dickinson and Company
– Berry Genomics Co., Ltd.
– BGI Group
– Biocartis Group
– Biocept, Inc.
– Biodesix, Inc.
– Biolidics Limited
– Bio-Rad Laboratories, Inc.
– Bio-Techne Corp.
– CareDx, Inc.
– Danaher Corp.
– Eurofins Scientific
– EXACT Sciences Corporation
– Illumina, Inc.
– Koninklijke Philips N.V.
– Merck KGaA
– Myriad Genetics, Inc.
– NeoGenomics Laboratories, Inc.
– OncoCyte Corporation
– Oxford Nanopore Technologies Limited
– Pacific Biosciences of California, Inc.
– Qiagen N.V.
– Roche Holding AG
– Takara Bio Inc.
– Thermo Fisher Scientific Inc.
– VolitionRx Limited
Tungkol sa StrategyHelix
Pagtanggi